Human CellExp™ LDLR, human recombinant

Biomolecule/Target: LDLR

Synonyms: LDLR, FH, FHC, LDLCQ2, Low-Density Lipoprotein (LDL) Receptor

Alternates names: LDLR, FH, FHC, LDLCQ2, Low-Density Lipoprotein (LDL) Receptor

Taglines: Mediates the endocytosis of cholesterol-rich LDL

Taglines: USA

Country of Animal Origin: USA

NCBI Gene ID #.: 3949

NCBI Gene Symbol: LDLR

Gene Source: Human

Accession #: P01130

Recombinant: Yes

Source: HEK293 cells

Purity by SDS-PAGE #: ≥90%

Assay: SDS-PAGE

Purity: N/A

Assay #2: N/A

Endotoxin Level: <1 EU/μg by LAL method

Activity (Specifications/test method): N/A

Biological activity: Measured in a competitive binding assay. When human LDL is immobilized at 1 μg/ml (100 μl/well), recombinant human LDLR inhibits 50% binding of biotinylated recombinant human LDLR (0.5 μg/ml) at the concentration range of 0.35 – 2.5 μg/ml.

Results: Measured in a competitive binding assay. When human LDL is immobilized at 1 μg/ml (100 μl/well), recombinant human LDLR inhibits 50% binding of biotinylated recombinant human LDLR (0.5 μg/ml) at the concentration range of 0.35 – 2.5 μg/ml.

Binding Capacity: N/A

Unit Definition: N/A

Molecular Weight: This protein is fused with a C-terminal 6×his tag and has a calculated MW of 86 kDa. The predicted N-terminal is Ala22 or Asp193. Corresponding to the mature and immature form, DTT-reduced protein migrates as 95-110 kDa &125-140 kDa polypeptide in SDS-PAGE resulting from different glycosylation.

Concentration: N/A

Appearance: Lyophilized

Physical form description: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally Mannitol or Trehalose is added as protectants before lyophilization.

Reconstitution Instructions: Centrifuge the vial prior to opening. Reconstitute in sterile PBS, pH 7.4 to a concentration of 50 µg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 month. For extended storage, it is recommended to store at -20°C.

Background Information: Low-Density Lipoprotein (LDL) Receptor, also known as LDLR, FH, FHC, LDLCQ2, and is a mosaic protein of ~840 amino acids (after removal of signal peptide) that mediates the endocytosis of cholesterol-rich LDL. It is a cell-surface receptor that recognizes the apoprotein B100 which is embedded in the phospholipid outer layer of LDL particles. The receptor also recognizes the apoE protein found in chylomicron remnants and VLDL remnants (IDL). It belongs to the Low density lipoprotein receptor gene family. LDL receptor complexes are present in clathrin-coated pits (or buds) on the cell surface, which when bound to LDL-cholesterol via adaptin, are pinched off to form clathrin-coated vesicles inside the cell. This allows LDL-cholesterol to be bound and internalized in a process known as endocytosis and prevents the LDL just diffusing around the membrane surface. This occurs in all nucleated cells (not erythrocytes), but mainly in the liver which removes ~70% of LDL from the circulation. Synthesis of receptors in the cell is regulated by the level of free intracellular cholesterol; if it is in excess for the needs of the cell then the transcription of the receptor gene will be inhibited. LDL receptors are translated by ribosomes on the endoplasmic reticulum and are modified by the Golgi apparatus before travelling in vesicles to the cell surface. LDL is directly involved in the development of atherosclerosis, due to accumulation of LDL-cholesterol in the blood. Atherosclerosis is the process responsible for the majority of cardiovascular diseases.

Amino acid sequence: N/A

Handling: Centrifuge the vial prior to opening.

Usage: For Research Use Only! Not to be used in humans